Sinovac Initiates the P-I Clinical Study for Vaccine Candidate Against COVID-19

 Sinovac Initiates the P-I Clinical Study for Vaccine Candidate Against COVID-19

Shots

  • The company has commenced P-I clinical study assessing its vaccine candidate vs PBO in 144 healthy adults, aged 18-59yrs, with two different dosages of the vaccine candidate, conducted in Jiangsu Province
  • The study evaluates the safety, tolerance, and preliminary immunogenicity of Sinovac’s SARS-CoV-2 vaccine under which two-thirds of the volunteers will be vaccinated with the investigational vaccine while one-third of volunteers will be treated with PBO
  • On April 13, 2020, the NMPA has approved P-I/II clinical study of its inactivated SARS-CoV-2 vaccine to evaluate the safety and immunogenicity of the vaccine

Click here to read full press release/ article | Ref: Business wire | Image: Behance

Related News: Dynavax Signs an Agreement with Sinovac to Develop a Vaccine for COVID-19

Shiwani Sharma

Shiwani Sharma is a Senior Editor at PharmaShots. She has in-depth knowledge of lifesciences industry including pharma and biotech sectors. She also covers news in field of Digital Health, Medtech and regulatory approvals from the US FDA, EU, and other global regulatory bodies in the industry. Additionally, she also writes Whitepapers, analysis reports, blogs on pharma and biotech industry. She is graduate in Biotechnology. She can be contacted on shiwani@pharmashots.com

Related post